Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children.
Clinical and serological follow-up studies were made on 257 healthy children who had received live varicella vaccine (strain Oka) in Showa Hospital. Good antibody responses were shown with a seroconversion rate of 98.4% (253/257) by the immune adherence hemagglutination test. Mild adverse reactions were observed in 11 of the vaccinated children. During observation periods of 6 months to 4 years, 6 of the 253 children who were successfully vaccinated contracted mild varicella, while all 4 vaccinees who showed no primary immune response contracted mild to moderate clinical varicella. It is concluded that this vaccine is highly immunogenic and causes few clinical reactions in normal children.
D000293:Adolescent; D000914:Antibodies, Viral / Q000096:biosynthesis; D002644:Chickenpox / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D005334:Fever / Q000209:etiology; D005500:Follow-Up Studies; D006386:Hemagglutination Tests; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines